A major provider of diabetes drugs and insulin, Lilly owned nearly 8. The two companies have been partners since 2018, when Lilly paid Sigilon $63 million for a licensing deal to develop cell therapes targeting type 1 diabetes and made an undisclosed equity investment. Lilly's portfolio of diabetes products contributed more than half of its total revenue in 2022